Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C N Williams

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Rhode Island Medical Journal|March 1, 1985
Overcoming barriers to identification and referral of alcoholics in a general hospital setting: one approachC N Williams, D C Lewis, J Femino, et al.
The Journal of Rheumatology|March 1, 1991
Antimitochondrial antibodies and antiphospholipid antibodiesJ V Jones, E Jones, D P Mosher, et al.
Gastroenterology|January 1, 1996
Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study GroupG R Greenberg, B G Feagan, F Martin, et al.
The New England Journal of Medicine|September 29, 1994
Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study GroupG R Greenberg, B G Feagan, F Martin, et al.
The American Journal of Gastroenterology|August 5, 2000
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitisS Hanauer, L I Good, M W Goodman, et al.
Scandinavian Journal of Gastroenterology|July 1, 1991
Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's diseaseJ Brynskov, L Freund, S Nørby Rasmussen, et al.
Gastroenterology|May 1, 1988
Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain reliefA P Archambault, P Pare, R J Bailey, et al.
Gastroenterology|October 31, 1998
Absence of linkage between inflammatory bowel disease and selected loci on chromosomes 3, 7, 12, and 16J D Rioux, M J Daly, T Green, et al.
Hepatology (Baltimore, Md.)|May 1, 1996
Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?M R Kilmurry, E J Heathcote, K Cauch-Dudek, et al.
Gastroenterology|December 13, 2000
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study GroupS Schreiber, R N Fedorak, O H Nielsen, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Rhode Island Medical Journal|March 1, 1985
Overcoming barriers to identification and referral of alcoholics in a general hospital setting: one approachC N Williams, D C Lewis, J Femino, et al.
The Journal of Rheumatology|March 1, 1991
Antimitochondrial antibodies and antiphospholipid antibodiesJ V Jones, E Jones, D P Mosher, et al.
Gastroenterology|January 1, 1996
Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study GroupG R Greenberg, B G Feagan, F Martin, et al.
The New England Journal of Medicine|September 29, 1994
Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study GroupG R Greenberg, B G Feagan, F Martin, et al.
The American Journal of Gastroenterology|August 5, 2000
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitisS Hanauer, L I Good, M W Goodman, et al.
Scandinavian Journal of Gastroenterology|July 1, 1991
Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's diseaseJ Brynskov, L Freund, S Nørby Rasmussen, et al.
Gastroenterology|May 1, 1988
Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain reliefA P Archambault, P Pare, R J Bailey, et al.
Gastroenterology|October 31, 1998
Absence of linkage between inflammatory bowel disease and selected loci on chromosomes 3, 7, 12, and 16J D Rioux, M J Daly, T Green, et al.
Hepatology (Baltimore, Md.)|May 1, 1996
Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?M R Kilmurry, E J Heathcote, K Cauch-Dudek, et al.
Gastroenterology|December 13, 2000
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study GroupS Schreiber, R N Fedorak, O H Nielsen, et al.
Pageof 11